Skip to main content
Altuviiio logo

Patient Experiences - Derek


“They measured my Factor VIII level, suggesting the treatment was working.”       
 

Contemplating a switch 

When I saw how much ALTUVIIIO helped my daughter, Brooklynn, I began thinking about switching myself. I wondered whether it would work for me, too.         
 

Looking at the factor levels 

Had I seen the data before switching, I probably would’ve had a good idea it would work. But once my care team took my PK Factor VIII level, I knew it was working for me.         
 

Life on ALTUVIIIO 

ALTUVIIIO has been amazing. When I initially switched, I saw my doctor and care team twice a month. Then I started going once a month. I just wish it could have come out sooner!       
 

Don’t hesitate to ask 

Even if patients seem satisfied with the way they’re currently managing hemophilia, I’d encourage doctors and care teams to ask them if their treatment is really working. And if they sense or realize it’s not, they should discuss if ALTUVIIIO could be the right fit!  

This testimonial reflects one patient’s experience and has not been clinically evaluated. It is not intended to imply typical outcomes or substitute for clinical evidence. Derek is a promotional speaker compensated by Sanofi.  

PK=pharmacokinetic.

Discover More Patient Experiences

Indication

ALTUVIIIO® is indicated for use in adults and pediatric patients with hemophilia A (congenital factor VIII deficiency) for:

  • Routine prophylaxis to reduce the frequency of bleeding episodes
  • On-demand treatment and control of bleeding episodes
  • Perioperative management of bleeding
Limitation of Use

ALTUVIIIO is not indicated for the treatment of von Willebrand disease.

Important Safety Information

Contraindications

ALTUVIIIO is contraindicated in patients who have had severe hypersensitivity reactions, including anaphylaxis, to the product or its excipients.

Warnings and Precautions
  • Allergic-type hypersensitivity reactions, including anaphylaxis, have occurred with ALTUVIIIO. Discontinue use of ALTUVIIIO if hypersensitivity reaction occurs and manage symptoms as appropriate.
  • Formation of neutralizing antibodies (inhibitors) to Factor VIII has been reported following administration of ALTUVIIIO. Monitor all patients for the development of Factor VIII inhibitors by appropriate clinical observations and laboratory tests.
  • If assessment of plasma Factor VIII activity is needed, it is recommended to use a validated one-stage clotting assay. The ALTUVIIIO Factor VIII activity level is overestimated by the chromogenic assay and a specific ellagic acid-based aPTT reagent in one-stage clotting assay by approximately 2.5-fold. If these assays are used, divide the result by 2.5 to approximate the patient's ALTUVIIIO Factor VIII activity level.
Adverse Reactions

The most common adverse reactions (>10% of subjects) reported in clinical trials were headache and arthralgia.

Indication

Important Safety Information

© 2026 Sanofi. All rights reserved. All trademarks mentioned are the property of the Sanofi group. MAT-US-2508205-v3.0-08/2026 Last Updated: August 2026